Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more
Market Cap & Net Worth: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (SHE:301096) has a market capitalization of $766.37 Million (CN¥5.62 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #11287 globally and #2640 in its home market, demonstrating a 9.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s stock price CN¥51.48 by its total outstanding shares 109228284 (109.23 Million).
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Market Cap History: 2021 to 2026
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $1.25 Billion to $766.37 Million (-14.21% CAGR).
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.70x
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s market cap is 0.70 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.25 Billion | $374.31 Million | $111.09 Million | 3.33x | 11.23x |
| 2022 | $999.69 Million | $607.41 Million | $194.16 Million | 1.65x | 5.15x |
| 2023 | $964.43 Million | $1.02 Billion | $271.97 Million | 0.95x | 3.55x |
| 2024 | $564.81 Million | $801.92 Million | -$52.74 Million | 0.70x | N/A |
Competitor Companies of 301096 by Market Capitalization
Companies near Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s market cap moved from $1.25 Billion to $ 766.37 Million, with a yearly change of -14.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥766.37 Million | -9.91% |
| 2025 | CN¥850.63 Million | +50.61% |
| 2024 | CN¥564.81 Million | -41.44% |
| 2023 | CN¥964.43 Million | -3.53% |
| 2022 | CN¥999.69 Million | -19.85% |
| 2021 | CN¥1.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $766.37 Million USD |
| MoneyControl | $766.37 Million USD |
| MarketWatch | $766.37 Million USD |
| marketcap.company | $766.37 Million USD |
| Reuters | $766.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.